The Nephrotic Syndrome Study Network (NEPTUNE)
Recruitment status was Recruiting
- The Nephrotic Syndrome Study Network (NEPTUNE) is a network of multidisciplinary researchers who are investigating why kidney disease happens. NEPTUNE researchers will collect kidney tissue and other samples (for example, blood and urine) from individuals who are scheduled to have kidney biopsies to determine the cause of protein in the urine (only one kidney biopsy is necessary).
- To collect kidney tissue, other samples, and data /information for continuing research into kidney diseases.
- Individuals at least 18 years of age who need to have a kidney biopsy to determine the cause of protein in the urine, do not have a systemic disease that is the cause of the their kidney disease, and have not received specific treatment for kidney disease.
- This study involves a screening and baseline visit and additional followup visits after the kidney biopsy.
- Participants will be screened with a medical history and physical examination, as well as blood and urine samples and collection of fingernail clippings. Participants will also complete questionnaires about their history of kidney problems.
- During the kidney biopsy, performed at the NIH Clinical Center, researchers will take an additional tissue sample for research.
- Participants will return for followup visits at NIH every 4 months in the first year, and every 6 months in the second through fifth years after the biopsy. Additional blood and urine samples will be collected at each visit, and fingernail clippings will also be collected annually by the study researchers.
- Treatment for kidney disease will not be provided as part of this protocol and instead will generally be provided by the patient s own physician.
Subjects received compensation for each visit to the NIH Clinical Center.
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Nephrotic Syndrome Study Network (NEPTUNE)|
- 1) Event rate of change in urinary proteinuria excretion. 2) Rate of change in renal function: 25mls/min/1.73m2 reduction, 50% decline in follow-up eGFR, end stage renal disease.
- 1) Quality of life2) New Onset Diabetes
|Study Start Date:||October 2010|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01240564
|Contact: Anaida Widell||(301) firstname.lastname@example.org|
|Contact: Jeffrey B Kopp, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Jeffrey B Kopp, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|